New targeted imaging agents and the diagnosis, prognosis of progressive disease

According to a media release issued today by Progenics Pharmaceuticals, early clinical studies of two of their investigational products — the imaging agents [123I]-MIP-1072 and [123I]-MIP-1095 — suggest potential of these two agents in enhancement of imaging techniques to identify the exact location of cancer in bone, tissue, and the prostate itself. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,134 other followers